→ Shares of Foamix Therapeutics $FOMX soared Tuesday night on news that their third Phase III study of a new acne med succeeded in delivering significant benefits. The numbers may not be overwhelming, with investigators noting that a “mean reduction in inflammatory lesion count at Week 12 relative to baseline was -16.93 for the FMX101 treatment group and -13.40 for the vehicle treatment group (p<0.0001).” But investors loved it. Shares rocketed up more than 50% in after-market trading and were still up 23% in early morning trading Wednesday.
→ A San Francisco-based biotech called Concentric Analgesics has won the FDA’s breakthrough drug designation for a non-opioid pain therapy. The injectable therapy is designed to desensitize nerve fibers without causing numbness, converting to capsaicin, a TRPV1-agonist. “Receiving Breakthrough Therapy designation for CA-008 is significant at this early stage of clinical development, and firmly supports the compelling data we have seen to date in post-surgical pain,” said CEO Frank Bellizzi.
→ Zai Lab is partnering with Novocure on their cancer therapy Optune, which uses electric fields to disrupt call division for cancer patients. The Shanghai-based Zai Lab plans to accelerate development work for China, saying it’s pleased to add a commercial-stage therapy to the pipeline.
→ Shire — soon to be melded into Takeda — says the European Commission has OK’d their application for Veyvondi, a new treatment for bleeding events in adults with von Willebrand disease.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription